Safety of high‐dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia
Open Access
- 20 June 2003
- journal article
- website
- Published by Wiley in British Journal of Haematology
- Vol. 122 (1) , 161-163
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancerBritish Journal of Cancer, 2002
- Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cellsBritish Journal of Haematology, 2002
- Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I–II studyBritish Journal of Haematology, 2002
- Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosisBlood, 2000